Speaker: Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
Date: January 21, 2022
ImpriMed was chosen as one of the finalists in the Technology Innovation showcase and received the Audience Choice award at the Animal Health, Nutrition, and Technology Innovation Europe 2022 event.
Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics
Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support
Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model